Quince Therapeutics CBO Purchases Shares & Warrants – Form 4 Filed

Rhea-AI Filing Summary

Quince Therapeutics, Inc. (QNCX) – Form 4 insider transaction

Chief Business, Operations and Commercial Officer Brendan Hannah reported a purchase of company securities on 18 June 2025.

• Common shares acquired: 37,736 shares
• Purchase price: $1.20 per share
• Post-transaction direct ownership: 334,276 common shares
• Derivative securities acquired: 37,736 warrants with a $1.20 exercise price, expiring 18 June 2030; cost recorded at $0.125 per warrant

The filing indicates a straightforward insider purchase (Transaction Code “A”) rather than a sale or option exercise. No other changes to ownership structure or additional transactions were disclosed.

Materiality assessment: The transaction increases Hannah’s direct equity stake by approximately 11 % (37,736 ÷ 334,276 ≈ 11 %), but the absolute dollar value is relatively modest (≈ $45,000 for the shares, ≈ $4,700 for the warrants). There is no indication of broader strategic developments, earnings information, or company-level financial impact within this filing.

Positive

• Insider purchase: Officer acquired 37,736 common shares, often interpreted as a vote of confidence.

Negative

• None.

Insights

Securities Analyst

TL;DR: Small insider buy suggests confidence; immaterial to fundamentals.

The Form 4 shows Brendan Hannah adding 37,736 common shares and an equal number of warrants. While insider buying is generally viewed as a constructive signal, the dollar size is minor relative to Quince Therapeutics’ market capitalization and daily trading volumes. The warrant terms (five-year tenor, $1.20 strike) mildly align the officer with shareholder upside. However, the filing contains no information on operational performance or strategic actions, so investors should treat the signal as incrementally positive, not thesis-changing.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Hannah Brendan

Role CBO, COO & CCO

Type	Security	Shares	Price	Value
Grant/Award	Warrants	37,736	$0.125	$5K
Grant/Award	Common Shares	37,736	$1.20	$45K

Holdings After Transaction: Warrants — 37,736 shares (Direct); Common Shares — 334,276 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hannah Brendan

(Last) (First) (Middle)

C/O QUINCE THERAPEUTICS, INC.

611 GATEWAY BLVD., SUITE 273

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Quince Therapeutics, Inc. [ QNCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CBO, COO & CCO

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/18/2025		A		37,736	A	$1.2	334,276	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	$1.2	06/18/2025		A		37,736		06/18/2025	06/18/2030	Common Shares	37,736	$0.125	37,736	D

Explanation of Responses:

	/s/ Brendan Hannah	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Quince Therapeutics (QNCX) shares did Brendan Hannah buy?

37,736 common shares were acquired on 18 June 2025.

At what price were the QNCX shares purchased?

The reported purchase price was $1.20 per share.

What is Brendan Hannah’s total direct shareholding after the transaction?

He now directly owns 334,276 common shares.

Were any derivative securities involved in the transaction?

Yes, 37,736 warrants with a $1.20 strike price expiring 18 June 2030 were acquired at $0.125 per warrant.

What role does Brendan Hannah hold at Quince Therapeutics?

He serves as CBO, COO & CCO of the company.

Does the filing indicate any sale of QNCX shares?

No. The Form 4 only reports acquisitions; there were no dispositions.